- IV (Adults and Children ): 150–200 mg/m2 every 6–8 wk or 75–100 mg/m2/day for 2 days every 6 wk or 40 mg/m2/day for 5 days every 6 wk.
- Intracavitary(Adults ): 61.6 mg (8 wafers) placed in cavity created during surgical resection of brain tumor.
High Alert
Contraindicated in:
Use Cautiously in:
Lung disease (↑ risk of pulmonary fibrosis)
;Derm: alopecia
GI: hepatotoxicity, nausea, vomiting, anorexia, diarrhea, esophagitis
GU: ↓fertility (men), renal failure
Hemat:
, LEUKOPENIA, THROMBOCYTOPENIALocal: pain at IV site
Resp: PULMONARY FIBROSIS
Drug-drug:
Absorption: IV administration results in complete bioavailability; following implantation, action is primarily local.
Distribution: Highly lipid soluble; readily penetrates CSF.
Half-Life: 15–75 min.
Instruct patient to notify health care provider if fever; chills; sore throat; signs of infection; lower back or side pain; difficult or painful urination; bleeding gums; bruising; petechiae; or blood in urine, stool, or emesis occurs. Caution patient to avoid crowds and persons with known infections. Instruct patient to use soft toothbrush and electric razor. Patients should be cautioned not to drink alcoholic beverages or to take products containing aspirin or NSAIDs.
Instruct patient to notify health care provider if shortness of breath or ↑ cough occurs.
NDC Code
